“On 29 November 2006 the Australian Government announced funding for a HPV vaccination program. When the vaccine was first introduced a catch-up program that consisted of two components (a school-based program and a community-based program) was instituted. The school-based catch-up program for 12 to 18 year old girls ceased in 2008. HPV immunization in the community-based catch-up program was available through general practice and community immunization services for 13 to 26 year old women.
Currently the HPV vaccines are registered for use in Australia in females aged 926 years and in males aged 915 years. The HPV vaccine is currently funded for 12-13 year old girls in the first year of secondary school with a recent decision to commence a funded program for boys commencing in 2013 in Australia.
When the HPV vaccine was first introduced people felt that the long-term effectiveness was uncertain and that it was unnecessary when a successful screening program was available for women. However the government decided to go ahead with introducing the vaccine.
QuestionsWhat factors do you think the Government took into account when making their decision?
Was a cost effectiveness study undertaken prior to the HPV vaccines being introduced? What were the findings from this study and how did the results compare to other vaccines being considered for introduction?
Do you think that the decision to implement the HPV vaccine was politically motivated? Discuss the arguments that were made for and against the introduction of the HPV vaccine campaign.
Uptake for the vaccine varies amongst different groups and nationalities. Discuss the barriers and facilitators impacting on uptake of the HPV vaccine around the world.
Why has the Government decided to extend the HPV vaccine campaign now to include boys?
What systems do developing countries need to consider for program monitoring?
Some refrences.
Shannon Stokley Jenny Jeyarajah David Yankey Maria Cano Julianne Gee Jill Roark C. Robinette Curtis Lauri Markowitz. Human Papillomavirus Vaccination Coverage Among Adolescents 20072013 and Postlicensure Vaccine Safety Monitoring 20062014 United States WeeklyJuly 25 2014 / 63(29);620-4
Australian Government Department of Health and Ageing. (2014). FAQs National HPV Vaccination Program Register. Retrieved from National HPV Vaccination Program Register: http://www.hpvregister.org.au/health-professionals/faq
Gretig D. M. Brotherton J. M. &Saville M. (2011).Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register Australia. Carlton South: CSIRO.
Judge K. (2012).Foundation Scholar Studies HPV Vaccine Uptake in College Women. American Nurse 44(6) 4-19.
Parry J. (2007). Vaccinating against Cervical Cancer: Since Last Year It Has Become Possible to Vaccinate against the Human Papillomavirus (HPV) That Causes Most Cases of Cervical Cancer but Countries Face Tough Decisions before Making the Vaccine Widely Available. Bulletin of the World Health Organization 85(2) 3-18.
Garland SM Brotherton JM Condon JR et al. Human papillomavirus prevalence among Indigenous and non-Indigenous Australian women prior to a national HPV vaccination program. BMC Medicine 2011;9:104.
Condon JR Armstrong BK Barnes A Cunningham J. Cancer in Indigenous Australians: a review. Cancer Causes and Control 2003;14:109-21
Gretig D. M. Brotherton J. M. &Saville M. (2011).Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register Australia. Carlton South: CSIRO.
Jin X. W. Lipold L. Sikon A. & Rome E. (2014). Human papillomavirus vaccine: Safe effective underused. Cleveland Clinic Journal of Medicine 49-60.
DSouza C. Sullivan Mort G. Zyngier S. Robinson P. &Schlotterlein M. (2013). Preventative Innovation: An Australian case study on HPV vaccination. Health Marketing Quarterly 30 (3) 206-220 DOI: 10.1080/07359683.2013.814486
Watson M. Shaw D. Molchanoff L. &McInnes C. (2008). Challenges lessons learned and results following the implrematation of a human papilloma virusschool vaccination program in South Australia. Australian and New Zealand Journal of Public Health 33 (4) 365 370.
Brandt H. M. (2009). HPV Vaccine Acceptance in a Clinic-Based Sample of Women in the Rural South. American Journal of Health Education 40(3) 5-23.
Jared R. (2010). HPV Vaccine Protects Women Even Longer. International Perspectives on Sexual and Reproductive Health 36(1) 4-32.
Manitoba center for health policy. (2009). Concept: Manitoba Immunization Monitoring System (MIMS). Retrieved from http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?conceptID=1032. (Accessed August 25 2014).
Partrick L. F. Z. (2009). Global safety of vaccines: strengthening systems for monitoring management and the role of GACVS. Retrieved from http://www.who.int/immunization_safety/global_committee/Global_Vaccine_Safety_GACVS_June_09.pdf. (Accessed
Australia Government Department of Health. The Australian Immunisation Handbook 10th edition 2013 (updated January 2014). pp.235-246. http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/EE1905BC65D40BCFCA257B26007FC8CA/$File/handbook-Jan2014v2.pdf
Australia Government Department of Health.National Cervical Screening Program. 2013. http://www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-about
National HPV Vaccination Program.About the HPV Register. 2014. www.hpvregister.org.au/parents-teens
NCIRS. Fact Sheet: HUMAN PAPILLOMAVIRUS (HPV) VACCINES FOR AUSTRALIANS: INFORMATION FOR IMMUNISATION PROVIDERS. 2013.
Dillner J ArbynMUngerEDilner L Monitoring of human papillomavirus vaccination.ClinExpImmunol. Jan 2011; 163(1): 1725.
Graham J. E. & Mishra A. (2011).Global challenges of implementing human papilomavirus vaccines. Retrieved from http://www.equityhealthj.com/content/10/1/27. (Accessed August 26 2014).
Judge K. (2012).Foundation Scholar Studies HPV Vaccine Uptake in College Women. American Nurse 44(6) 4-19.
Manitoba center for health policy. (2009). Concept: Manitoba Immunization Monitoring System (MIMS). Retrieved from http://mchp-appserv.cpe.umanitoba.ca/viewConcept.php?conceptID=1032. (Accessed August 27 2014).
Human papillomavirus vaccine support accessed 28 August 2014 < http://www.gavi.org/support/nvs/human-papillomavirus-vaccine-support/>. Markowitz L Tsu V Deeks SL Cubie H Wang Sam Vicari AS Brotherton JML 2014 Human papillomavirus vaccine introduction- the first five years Vaccine vol. 32 issue 10 pp 139- 148 accessed 28 August 2014 via Elsevier. WHO 2010 Human papillomavirus vaccine; WHO position paper accessed 29 August 2014 .
Ashton T and Sopina E 2012 Value for money from HPV vaccination and cervical screening Human vaccines and immunotherapeutics vol. 8 no. 6 pp.828-30
Choi HC Leung GM Woo PP Jit M Wu JT 2013 Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents Vaccine vol. 32 no. 1 pp.78-84.
Dhauwers KWM Gadet PFE Donders ART Tjalma WA 2013 Impact of medical education on knowledge and attitudes regarding the human papillomavirus and vaccination: comparison before and 6 years after the introduction on the vaccines Vaccine vol. 31 no. 49 pp.5943-47.
Herweijer E Level A Ploner A Eloranta A Simard JF Dillner J Netterlid E Sparen P Arnheim-Dalstrom L 2014 Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condylomata JAMA vol. 311 no. 6 pp.597-603
Ladner J Besson MH Hampshire R Tapert L Chirenje M Saba J 2012 Assessment of eight HPV vaccination programs implemented in lowest income countries BMC Public Health vol. 12 no. 370 pp.1-8
Levin A. Wang S. Levin C. Tsu V. &Hutubessy R. (2014). Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries. PLoS One 9(6) doi: 10.1371/journal.pone.0101114 Accessed 28.08.14 from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072768/
MacNeil A. Dietz V &Cherian T. (2014). Vaccine preventable diseases: Time to re-examine global surveillance data? Vaccien 32 (20) 2315-2320
Schlipkter U Flahault A. (2010). Communicable diseases: achievements and challenges for public health. Public Health Reviews;32:90-119.
St. Louis M. (2012).Global health surveillance. MMWR 61 (3) 15-19
NNii.(2010). Monitoring Vaccine safety. Retrieved from http://www.immunizationinfo.org/parents/why-immunize/monitoring-vaccine-safety. (accessed August 27 2014).
WHO.(2014). Immunization Surveillance assessment and monitoring. Retrieved from http://www.who.int/immunization/monitoring_surveillance/en/. (Accessed August 26 2014).
Chang Y Brewer NT Rinas AC Schmitt K Smith JS 2009 Evaluating the impact of human papilloma virus vaccines Vaccine vol. 27 issue 32 pp. 4355-4362 accessed 30 August 2014 from Elsevier.
Hariri S Dunne E Soraiya M Unger E Markowitz L 2014 Centre for Disease a Control Manual for surveillance of vaccine preventable diseases accessed 31 August 2014 .
Judge K. (2012).Foundation Scholar Studies HPV Vaccine Uptake in College Women. American Nurse 44(6) 4-19.
WHO.(2014). Immunization Surveillance assessment and monitoring. Retrieved from http://www.who.int/immunization/monitoring_surveillance/en/. (Accessed August 29 2014).
Cutts F. T. (2007). Human Papillomavirus and HPV Vaccines: A review/Virus Du PapillomeHumainetVaccins Anti-VPH: bilan/PapilomavirusHumanos Y Vacunas Anti-PVH: Revision. Bulletin of the World Health Organization 85(9) 3-21.
Graham J. E. & Mishra A. (2011).Global challenges of implementing human papilomavirus vaccines. Retrieved from HYPERLINK http://www.equityhealthj.com/content/10/1/27 (Accessed August 20 2014).
“
